drugset
drugset / Trial / NCT04475107

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

NCT04475107 ↗

Phase 2 Completed 113 enrolled Shin Poong Pharmaceutical Co. Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19 patients.

Timeline

Start
2020-07-09
Primary completion
2021-03-25
Completion
2021-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 60 mg —
Subject Pyronaridine Unknown 180 mg —

Indications

COVID-19